LSD shows promise for reducing anxiety in drugmaker's midstage study
6 days ago
- #psychedelics
- #FDA
- #mental-health
- LSD shows promise in reducing anxiety symptoms in a midstage study by Mindmed.
- Benefits of LSD lasted up to three months in patients with generalized anxiety disorder.
- The study tested several doses, with the highest (100 micrograms) showing significant anxiety reduction.
- Psychedelics like LSD, psilocybin, and MDMA are being reconsidered for mental health treatments.
- The FDA has designated LSD as a potential 'breakthrough' therapy.
- Previous psychedelic research from the 1950s-60s was halted due to legal restrictions.
- Modern studies aim to address past flaws, including separating drug effects from therapy.
- Patients in the study experienced side effects like hallucinations, nausea, and headaches.
- Mindmed plans late-stage trials to seek FDA approval for LSD as an anxiety treatment.
- Interest in psychedelic therapy is growing, including from government officials.